HMGA1 is a structural chr6 remodeling protein that binds preferentially to AT-rich DNA regions and functions as a transcriptional regulator with pleiotropic roles in development and cancer. Mechanistically, HMGA1 acts as an epigenetic gatekeeper by recruiting active histone marks (H3K4me3, H3K27Ac) to target gene promoters, thereby opening chr6 architecture and enhancing transcription 12. HMGA1 overexpression is characteristic of diverse malignant tumors including colorectal, pancreatic, esophageal, and prostate cancers 3245. In colorectal cancer, HMGA1 drives tumorigenesis by upregulating fatty acid synthase and enhancing lipid synthesis through transcriptional activation of SREBP1 3. In colon cancer, HMGA1 amplifies oncogenic Wnt signaling by upregulating the stem cell regulator ASCL2, promoting stem cell states while depleting differentiated enterocytes 1. In pancreatic cancer, HMGA1 induces FGF19 expression to promote both tumor growth and desmoplastic stroma formation 2. Conversely, HMGA1 suppresses anti-tumor immunity in esophageal cancer by inhibiting STING-mediated type I interferon secretion and impairing tumor-infiltrating lymphocyte recruitment 4. These findings establish HMGA1 as a critical oncogenic driver across multiple cancer types, suggesting it represents a viable therapeutic target.